Key statistics
On Friday, Regenxbio Inc (RGNX:NSQ) closed at 8.68, 72.39% above the 52 week low of 5.04 set on Apr 09, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 8.91 |
---|---|
High | 9.11 |
Low | 8.61 |
Bid | 8.55 |
Offer | 9.15 |
Previous close | 9.06 |
Average volume | 660.89k |
---|---|
Shares outstanding | 50.39m |
Free float | 45.88m |
P/E (TTM) | -- |
Market cap | 437.37m USD |
EPS (TTM) | -3.11 USD |
Data delayed at least 15 minutes, as of Jul 11 2025 21:00 BST.
More ▼
- REGENXBIO Announces Publication of Preclinical Results Demonstrating Functional Benefits of Novel Microdystrophin Construct in RGX-202 Investigational Gene Therapy for Duchenne Muscular Dystrophy
- REGENXBIO REPORTS NEW POSITIVE FUNCTIONAL DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202
- REGENXBIO to Host Webcast Discussing Interim Functional Data from the Phase I/II AFFINITY DUCHENNE® Trial of RGX-202
- REGENXBIO Announces Strategic Royalty Monetization Agreement for Up to $250 Million
- FDA Accepts Biologics License Application for Mucopolysaccharidosis II Treatment
- REGENXBIO Announces FDA Acceptance and Priority Review of the BLA for RGX-121 for MPS II
- REGENXBIO Reports First Quarter 2025 Financial Results and Recent Operational Highlights
- REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 28th Annual Meeting
- REGENXBIO to Participate in Upcoming Investor Conferences
- REGENXBIO to Host Conference Call on May 12 to Discuss First Quarter 2025 Financial Results and Recent Operational Highlights
More ▼